Bespoke Extracts, Inc.
BSPKAbout the company
Bespoke Extracts, Inc., together with its subsidiary, Bespoke Extracts Colorado, LLC, produces and sells pre-rolled marijuana cigarettes in the United States. The company owns, manufactures, and distributes a diverse portfolio of cannabis consumer packaged goods under the Fresh Joints, Doobskis, DutchBlunts, and Wee Joints brand names.
Investment snapshot
Positive
1
BUY / PASS
Neutral / negative
2 / 13
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Annual history · FY 2024 Latest source filing: 2025-11-12 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-21 Score computed: 2026-11-14 | Annual history · FY 2024 · Balance sheet at 2025-09-30 · TTM ended 2025-09-30 Latest source filing: 2025-11-12 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-21 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-21 Score computed: 2026-11-14 | Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Market data at 2026-11-01 Latest source filing: 2025-11-12 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30 Latest source filing: 2025-11-12 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2024 Latest source filing: 2025-04-21 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment · Balance sheet at 2025-09-30 Latest source filing: 2025-11-12 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-21 Score computed: 2026-11-14 | Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Market data at 2026-11-01 Latest source filing: 2025-11-12 Score computed: 2026-11-14 | Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2025-09-30 Latest source filing: 2025-11-12 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-21 Score computed: 2026-11-14 | TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2024 Latest source filing: 2025-11-12 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-21 Score computed: 2026-11-14 | Annual history · FY 2024 · Balance sheet at 2025-09-30 Latest source filing: 2025-11-12 Score computed: 2026-11-14 | TTM ended 2025-09-30 · Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-11-12 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 2✗ 26▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-387.8%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-387.8%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per ShareN/A (negative BVPS)✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation Reasonableness✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-13178.3%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical Average✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low120% of trailing low ($0.00)✓Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-10819.96%; #6246/6340 (top 98.5%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization-384.4058; #6410/6449 (top 99.4%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per ShareN/A (non-positive TBVPS)✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+210.7593; #64/5247 (top 1.2%)✓OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-13178.35%; #4479/4519 (top 99.1%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-99.74%; #6173/6202 (top 99.5%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy✗BuffettPositive and growingFCF Positive and Growing$-0.9M✗LynchPositive and growingOperating Cash Flow$-0.3M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-80.71%, ROA=-288.92%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-13178.3%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/3 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-13296.6%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/14 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-0.9M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-13178.35%; #4479/4519 (top 99.1%)✗OshaughnessyTop 10% of eligible cross-section - Profitability6% pass✓ 5✗ 30▾
15 of 16 flag BSPK's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)1/16 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthNet Income Positive (10+ years)1/16 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-98.4%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-89.0% (latest)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROEN/A (negative equity)✗Lynch> 15%EBIT / Enterprise Value-387.8%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-387.8%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-288.92%✗PiotroskiROA > 0ROA Change YoY-418.46% -> -288.92% (delta: +129.54%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-80.71%, ROA=-288.92%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY43.7% -> 40.5%✗PiotroskiImproved YoYPre-Tax Income / Revenue-51.3%✗Dreman>= 8%Net Income / Shareholders' Equity✗Dreman> 12%Margin of Safety✗PabraiP/B < 1.5 or P/E < 15Return on Equity-130.2% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency1/14 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-45.0%✗Ackman>= 15%Net Income / Shareholders Equity✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-118011.6% (2022) -> -89.0% (2024)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 66.3% -> 40.5%, operating margin -118011.6% -> -89.0%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-10819.96%; #6246/6340 (top 98.5%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+227.25%; #27/3702 (top 0.7%)✓AsnessTop 30% of eligible cross-sectionNet income / positive book equity✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-9.9352; #5691/5884 (top 96.7%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years1/10 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Verdicts7% pass✓ 1✗ 13▾
Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS
Overall verdict✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (0/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 5)✗DremanFAIL (0/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (2/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage8% pass✓ 1✗ 14▾
11 of 12 flag BSPK's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: N/A (negative equity), IC: -16.6x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / EquityN/A (negative equity)✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities0.11✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt LevelsN/A (non-positive equity)✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-16.6x, D/EBITDA=N/A (D&A unavailable)✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section - Growth13% pass✓ 3✗ 10▾
7 of 8 flag BSPK's growth — Graham, Lynch, Dreman +4 more
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: 105.9% vs Rev: 42.3%✗LynchInventory growth < Revenue growthEPS Growth Direction$0.00 (2011) -> $-0.10 (2024)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency1/14 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth42.3%✓Ackman>= 5%Positive EPS Growth Frequency2/5 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 66.3% -> 40.5%, operating margin -118011.6% -> -89.0%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR78.2%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency13% pass✓ 2✗ 9▾
7 of 8 flag BSPK's efficiency — Graham, Buffett, Greenblatt +4 more
Current Ratio0.11✗Graham>= 2.0ROIC (3-5 yr avg)-32.6%✗Buffett> 10%ROIC - WACC-42.6%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)✗Greenblatt> 25%Current Ratio Change YoY0.08 -> 0.15✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY2.22x -> 3.11x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities0.11✗Dreman> 1.5Return on Invested CapitalN/A (non-positive invested capital)✗Munger> 15%ROIC (high and growing)FY2022: ROIC=unavailable; FY2023: ROIC=unavailable; FY2024: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/1 years above 12% (latest -30.6%)✗SleepROIC > 12% in a majority of years
Business & financials
Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2024
Issued 9.7% of shares last year, 12.1% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2025-09-30 2024-10-01 – 2025-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, capex. | Q3 FY 2025 2025-07-01 – 2025-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q2 FY 2025 2025-04-01 – 2025-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q1 FY 2025 2025-01-01 – 2025-03-31 Sources | FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
| FY 2020Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.8Kcurrent | -- | -- | -- | $1.3Mest. | $1.0Mest. | $611.7Kest. | $9.5Mest. | $691.1Mest. |
| Revenue | $1.4M | $467.9K↑69% | $390.6K↑40% | $263.2K↑1% | $1.1M↑42% | $785.5K↑22954% | $3.4K↓90% | $35.6K↑342% | $8.1K |
| Operating Income | -$640.3K | -$53.9K↑79% | -$162.0K↑35% | -$245.3K↑19% | -$994.6K↑32% | -$1.5M↑63% | -$4.0M↓316% | -$965.6K↑76% | -$4.0M |
| Net Income | -$730.6K | -$78.1K↑72% | -$205.1K↑21% | -$260.5K↑17% | -$1.0M↑30% | -$1.5M↑64% | -$4.1M↓326% | -$965.6K↑79% | -$4.6M |
| EPS (Diluted) | -- | $-0.01↑67% | $-0.02↑33% | $-0.02↑33% | $-0.10↑33% | $-0.15↑66% | $-0.44↓132% | $-0.19↓375% | $-0.04 |
| Gross Margin | 47.2% | 50.0%↑21% | 50.6%↑33% | 42.1%↑7% | 40.5%↓7% | 43.7%↓34% | 66.3%↑7% | 61.8%↑10% | 56.5% |
| Operating Margin | -45.0% | -11.5%↑88% | -41.5%↑54% | -93.2%↑20% | -89.0%↑53% | -187.4%↑100% | -118011.6%↓4247% | -2714.9%↑95% | -49857.5% |
| ROE | 28.1% | — | — | — | 49.6%↓42% | 86.0%↓86% | 612.4%↑1362% | -48.5%↓105% | 903.5% |
| Total Debt | $194.0K | $194.0K↑676% | $184.0K↓81% | $2.2M↑132% | $310.0K↓64% | $849.5K↑104% | $415.5K↓17% | $500.0K | $500.0K |
| Shareholders' Equity | -$2.6M | -$2.6M↓11% | -$2.5M↓17% | -$2.3M↓18% | -$2.1M↓21% | -$1.7M↓157% | -$672.1K↓134% | $2.0M↑487% | -$513.7K |
| Current Ratio | 0.11 | 0.11↑46% | 0.10↑23% | 0.10↑29% | 0.15↑95% | 0.08↓41% | 0.13↓99% | 9.71↑4881% | 0.19 |
| Debt / Equity | -0.07 | -0.07↓596% | -0.07↑84% | -0.93↓96% | -0.15↑70% | -0.49↑20% | -0.62↓346% | 0.25↑126% | -0.97 |
| Operating Cash Flow | -$259.7K | -$19.6K↑31% | -$31.0K↓10% | -$72.9K↑25% | -$289.8K↑30% | -$415.2K↑48% | -$798.1K↑23% | -$1.0M↓124% | -$465.2K |
| Free Cash Flow | -- | -$19.6K | -$31.0K | -$672.9K | -$889.8K | -- | -$805.3K↑23% | -$1.0M | -- |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
BSPK vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |